1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Jason J. Luke, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors ivosidenib and nivolumab - Advanced Solid Tumor, IDH1 Mutation | Phase 2 | Completed | Jason J. Luke, MD | 15 | 2021-09-20 | 2025-02-27 |
| Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma encorafenib, nivolumab, ipilimumab - Melanoma | Phase 1 / Phase 2 | Terminated | Jason J. Luke, MD | 2 | 2021-05-28 | 2024-05-23 |
Nivolumab (2) · Ipilimumab (1) · binimetinib (1) · encorafenib (1) · ivosidenib (1)
United States (2)
Jason J Luke, MD (1) · Jason J Luke, MD, PhD (1)